Suche klinische Studie
Weitere Suchoptionen
79 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
BELGIEN
ANTWERPEN
ANTWERPEN-EDEGEM
Functional Respiratory Imaging (FRI) to Assess the Short-term Effect of the Product ORKAMBI (Lumacaftor/ Ivacaftor) on Lung Function in ORKAMBI naive Patients With Cystic Fibrosis Homozygous for Phe508del
University Hospital of Antwerp - UZA
Muco-Referentiecentrum (kinderen afdeling)
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis- BE
Institution: Information not provided - BE
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
Ship-CT: A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks on lung structure in patients with Cystic Fibrosis at 3-6 years of age, in parallel with the North American SHIP clinical trial, as measured by computed tomography (CT) - BE
Institution: Information not provided - BE
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Effects of the Addition of the SIMEOX Device on Autogenic Drainage in Patients With Cystic Fibrosis
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
ALPINE2: Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects With Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas Aeruginosa (PA) Infection/Colonization - BE
Hôpital Universitaire des Enfants Reine Fabiola - HUDERF
Service de Pneumologie-Allergologie
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MACRODUCT-3710: Efficacy of a New Sweat Collection Support: Impact on Neonatal Screening and Early Treatment of Cystic Fibrosis
Université Catholique de Louvain (UCL)
Louvain centre for Toxicology and Applied Pharmacology
BELGIEN
VLAAMS BRABANT
LEUVEN
A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects - BE
UZ Leuven - Campus Gasthuisberg
Mucocentrum
BELGIEN
VLAAMS BRABANT
LEUVEN
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation - BE
UZ Leuven - Campus Gasthuisberg
UZ Leuven
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
ANAKIN: Phase IIa, randomisierte, Placebo-kontrollierte, doppel-blinde, cross-over Studie zur Untersuchung von Sicherheit und Wirksamkeit der subkutanen Verabreichung von Anakinra bei Patienten mit Cystischer Fibrose (CF)
Universitätsmedizin Heidelberg
Zentrum für Seltene Erkrankungen (ZSE) Heidelberg
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine Phase III Rollover-Studie zur Untersuchung der Sicherheit und Wirksamkeit von langfristig angewendetem Lumacaftor in Kombination mit Ivacaftor bei Patienten mit Mukoviszidose ab einem Alter von 6 Jahren und mit homozygoter F508del-CFTR-Mutation -DE-
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine explorative Phase 2, 2-teilige, randomisierte, doppelblinde, Placebo-kontrollierte Studie mit einer langfristigen, offenen Labelperiode zur Untersuchung der Auswirkungen von Lumacaftor/Ivacaftor auf den Krankheitsverlauf in Probanden im Alter von 2 bis 5 Jahren mit Mukoviszidose, homozygot für F508del
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine offene Phase-3-, 2-armige Studie zur Evaluierung der Sicherheit und Pharmakodynamik der langfristigen Ivacaftor-Behandlung bei Patienten mit zystischer Fibrose, die bei Behandlungsbeginn jünger als 24 Monate sind und eine bestätigte Ivacaftor-responsive Mutation aufweisen
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Phase 1b, Randomisierte, doppelblinde, Placebo-kontrollierte, Dosis-Eskalationsstudie zur Beurteilung der Sicherheit, Verträglichkeit und Pharmakokinetik von QR-010 bei CF-Patienten mit homozygoter deltaF508-Mutation
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Phase-Ib/IIa-Studie zur Untersuchung der Sicherheit, Verträglichkeit, Pharmakokinetik und Pharmakodynamik von oral inhalierten Mehrfachdosen von POL6014 bei Patienten mit zystischer Fibrose
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine randomisierte, doppelblinde, placebokontrollierte Phase-Ib-Studie zur Untersuchung der Sicherheit, Verträglichkeit und Pharmakokinetik von inhalierten CHF 6333 nach einmaliger und wiederholter aufsteigender Dosierung bei Patienten mit Mukoviszidose und nicht mukoviszidoser Bronchiektasie
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
VX19-445-115: Eine offene Phase-3b-Studie zur Evaluierung der Sicherheit der Kombinationstherapie Elexacaftor/Tezacaftor/Ivacaftor bei Mukoviszidose
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
BERLIN
Eine doppelblinde , randomisierte, Placebo-kontrollierte, multizentrische Phase 2-Studie zur Untersuchung der Sicherheit, Verträglichkeit, Pharmakokinetik und Wirksamkeit von JBT-101 bei Patienten mit Zystischer Fibrose
Otto-Heubner-Centrum für Kinder- und Jugendmedizin
Klinik für Pädiatrie mit Schwerpunkt Pneumologie und Immunologie
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
EARLY: Eine randomisierte, doppelblinde, Placebo-kontrollierte, multizentrische Crossover-Studie zur Untersuchung der Wirksamkeit und Sicherheit von inhaliertem Tobramycin zur Behandlung früher Infektionen mit Pseudomonas Aeruginosa bei Mukoviszidose-Patienten zwischen 3 Monaten und 7 Jahren (Phase III) - Completed
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Schwerpunkt Allergologie, Pneumologie und Mukoviszidose
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
Eine doppelblinde , randomisierte, Placebo-kontrollierte, multizentrische Phase 2-Studie zur Untersuchung der Sicherheit, Verträglichkeit, Pharmakokinetik und Wirksamkeit von JBT-101 bei Patienten mit Zystischer Fibrose
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Schwerpunkt Allergologie, Pneumologie und Mukoviszidose
DEUTSCHLAND
Mecklenburg-Vorpommern
ROSTOCK
TR02-110: Offene Studie zur Untersuchung der Langzeitsicherheit und Langzeitverträglichkeit von Arikace bei Mukoviszidose-Patienten mit chronischer Pseudomonas Aeruginosa-Infektion (Phase III)
Universitäts-Kinder- und Jugendklinik Rostock
Abteilung Pneumologie und Allergologie
DEUTSCHLAND
Nordrhein-Westfalen
DÜSSELDORF
IMPACTT-PsAer-IgY: Prospektive, randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Phase III-Studie zur Einschätzung der klinischen Wirksamkeit und Sicherheit des polyclonalen Anti- Pseudomonas-Antikörpers IgY zur Vermeidung des Wiederauftretens einer Pseudomonas Aeruginosa-Infektion bei Patienten mit zystischer Fibrose
Universitätsklinikum Düsseldorf
Klinik für Allgemeine Pädiatrie, Neonatologie und Kinderkardiologie
DEUTSCHLAND
Thüringen
JENA
Colistin nasal CF pilot: Sinonasale Inhalation von Colistin mit dem Pari Sinus-Vernebler bei Patienten mit zystischer Fibrose und Pseudomonasnachweis im Nasen-/Nasennebenhöhlenbereich. Offene, multizentrische, prospektive Phase II klinische Studie
Universitätsklinikum Jena
Klinik für Kinder- und Jugendmedizin: Sektion Pneumologie/Allergologie/Mukoviszidosezentrum
DEUTSCHLAND
Thüringen
JENA
Eine Phase 3-Studie zur Wirksamkeit und Sicherheit von Ataluren (PTC124®) bei Mukoviszidose-Patienten mit Nonsense Mutation - Completed
Universitätsklinikum Jena
Klinik für Kinder- und Jugendmedizin: Sektion Pneumologie/Allergologie/Mukoviszidosezentrum
ESTLAND
Tartu
TARTU
EDIT : A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder from a Modified Manufacturing Process (TIPnew)
Children's Clinic - Tartu University Hospital
Centre of Allergic Diseases
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. aeruginosa in Cystic Fibrosis Subjects Aged from 3 Months to less than 7 years - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function-FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
BRON
Ship-CT: A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks on lung structure in patients with Cystic Fibrosis at 3-6 years of age, in parallel with the North American SHIP clinical trial, as measured by computed tomography (CT) - FR
CHU de Lyon HCL - GH Est-Hôpital Femme Mère Enfant
Service de pneumologie et allergologie pédiatrique, mucoviscidose
FRANKREICH
HAUTS-DE-FRANCE
LILLE
TOBRAMUC : Evaluation of the effectiveness of a treatment involving one (or several) antibiotic (s) with 14-day tobramycin (Nebcine®) by intravenous injection versus the same antibiotic treatment (s) associated with only 5 days of tobramycin (Nebcine®) by intravenous injection followed tobramycin aerosol (Tobi®) for 9 days in the context of cystic fibrosis (Phase III)
CHRU de Lille - Hôpital Albert Calmette
Clinique de Pneumologie - CRC mucoviscidose
IRLAND
County Cork
CORK
IMPACTT (PsAer-IgY): Prospective, randomized, placebo-controlled, double blind, multicenter phase III study to evaluate clinical efficacy and safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in prevention of recurrence of Pseudomonas Aeruginosa infection in Cystic Fibrosis patients - IE
Cork University Hospital
Department of Respiratory Medicine
ITALIEN
LAZIO
ROMA
Experimental study, randomized, open label, to evaluate the effect of docosahexaenoic acid (DHA) supplementation versus 5-methyltethrahydrofolate + B12 vitamin and DHA, in cystic fibrosis patients and pancreatic insufficiency
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O.C. di Fibrosi Cistica
ITALIEN
LAZIO
ROMA
Open multicenter phase III study to asses safety and efficacy of inhalatory Aztreonam Lisine versus Tobramycin solution for nebulization, in the context of a intermittent antibiotic aerosol regimen in patients with cycstic fibrosis - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O.C. di Fibrosi Cistica
NIEDERLANDE
Utrecht
UTRECHT
The TRIO study: Genistein as an add-on treatment for CF?
UMC Utrecht - Universitair Medisch Centrum Utrecht
Afdeling Longziekten voor kinderen
NIEDERLANDE
Zuid-Holland
ROTTERDAM
Ship-CT: A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderlongziekten
OSTERREICH
TIROL
INNSBRUCK
LCI-OUT: Lung Clearance Index as an OUTcome parameter to detect the efficacy of Aztreonam Lysine Inhalation in cystic fibrosis patients with near normal spirometry - an observational proof-of concept study
Medizinische Universität Innsbruck
Universitätsklinik für Pädiatrie III
OSTERREICH
TIROL
INNSBRUCK
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis - AT
Medizinische Universität Innsbruck
Universitätsklinik für Pädiatrie III
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
ALPINE2: Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects With Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas Aeruginosa (PA) Infection/Colonization - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Randomized, Double Blind, Dose-finding Study of Inhaled Oligosaccharide (OligoG) vs Placebo in Patients With Cystic Fibrosis (Phase II-III) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
WIEN
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie
POLEN
Poznan
POZNAN
An Open-label, Multicenter, Randomized, Cross-over Study to Compare the Safety and Efficacy of PANZYTRAT 25 000 to KREON 25 000 in the Control of Steatorrhea in Subjects Aged 7 Years and Older With Cystic Fibrosis and Exocrine Pancreatic Insufficiency - PL
Szpital Kliniczny im. K. Jonschera
Klinika Gastroenterologii Dzieciecej I Chorob Metabolicznych
SPANIEN
Andalucía
SEVILLA
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis - ES
Hospital Universitario Virgen del Rocío
Unidad de Neumología y Cirugía Torácica
SPANIEN
Andalucía
SEVILLA
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) - ES
Hospital Universitario Virgen del Rocío
Unidad de Neumología y Cirugía Torácica
SPANIEN
Cataluña
BARCELONA
A Phase 3b, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 6 Through 11 Years of Age Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) - ES
Hospital Universitari Vall d'Hebron
Unidad de Neumología Pediátrica y Fibrosis Quística
SPANIEN
Cataluña
BARCELONA
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis - ES
Hospital Universitari Vall d'Hebron
Unidad de Neumología Pediátrica y Fibrosis Quística
SPANIEN
Cataluña
BARCELONA
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis - ES
Hospital Universitari Vall d'Hebron
Servicio de Neumología
SPANIEN
Cataluña
BARCELONA
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) - ES
Hospital Universitari Vall d'Hebron
Servicio de Neumología
SPANIEN
Cataluña
BARCELONA
Ship-CT: A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - ES
Vall d'Hebron Institut de Recerca VHIR
Área de Obstetricia, Pediatría y Genética
SPANIEN
Cataluña
SABADELL
Effect of nebulized bicarbonate on bacterial infections in patients with cystic fibrosis. Randomized clinical trial (Phase II) - ES
Corporación Sanitaria Parc Taulí. Hospital de Sabadell
Hospital de Sabadell
SPANIEN
Cataluña
SABADELL
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis - ES
Corporación Sanitaria Parc Taulí. Hospital de Sabadell
Hospital de Sabadell
SPANIEN
Comunidad Valenciana
VALENCIA
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) - ES
Hospital Universitario y Politécnico La Fe
Servicio de Neumología
SPANIEN
Comunidad Valenciana
VALENCIA
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis - ES
IIS La Fe - Instituto de Investigación Sanitaria La Fe
Unidad de Investigación Clínica y de productos con Actividad Biológica
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
ALPINE2: Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects With Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas Aeruginosa (PA) Infection/Colonization - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A multicenter, open-label Phase 2 study with escalating doses of MS1819-SD on top of a stable dose of PPEs, to investigate the efficacy and safety of this combination for the compensation of severe exocrine pancreatic insufficiency in CF patients not fully compensated with only PPEs - ES
Institution: Information not provided - ES
SPANIEN
Madrid
MADRID
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis - ES
Hospital Universitario 12 de Octubre
Servicio de Neumología
SPANIEN
Madrid
MADRID
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis - ES
IdiPAZ - Instituto de Investigación Sanitaria del Hospital Universitario La Paz
Unidad Central de Investigación Clínica y Ensayos Clínicos del Hospital La Paz
SPANIEN
Murcia
EL PALMAR, MURCIA
A Phase 3b, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 6 Through 11 Years of Age Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) - ES
Hospital Clínico Universitario Virgen de la Arrixaca
Servicio de Pediatría
SPANIEN
Murcia
EL PALMAR, MURCIA
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) - ES
Hospital Clínico Universitario Virgen de la Arrixaca
Servicio de Pediatría
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Proteostasis PTI428: A Phase I/II Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects with Cystic Fibrosis -GB
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
VX11-661-101: A Phase 2, Multicenter, Double Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subjects with Cystic Fibrosis, Homozygous or Heterozygous for the F508del CFTR Mutation - UK
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Merseyside
LIVERPOOL
'The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of flucloxacillin as a longterm prophylaxis agent for infants with CF'
Alder Hey Children's Hospital
VEREINIGTES KONIGREICH
Nottinghamshire
NOTTINGHAM
Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 (GIFT-CF2
University of Nottingham Research Innovation Services
University of Nottingham (UK)
VEREINIGTES KONIGREICH
West Yorkshire
LEEDS
HFNT During Exercise in CF (Cystic Fibrosis)
Leeds Children's Hospital
Leeds Regional Paediatric Cystic Fibrosis Centre
Multinationale klinische Studie(n)
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the DeltaF508-CFTR Gene Mutation (Phase II) (coordination)
Institution: Information not provided - FR
FRANKREICH
OCCITANIE
LANGLADE
IRLAND
County Cork
CORK
CFMATTERS: Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
University College Cork
UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND
ITALIEN
EMILIA ROMAGNA
PARMA
A multicentre, multinational, open-label, randomised, parallel group clinical trial of Tobrineb®/Actitob®/Bramitob® (Tobramycine solution for nebulisation, 300 mg twice daily in 4 mL unit dose vials) compared to TOBI® in the treatment of patients with cystic fibrosis and chronic infection with Pseudomonas aeruginosa (Phase III) (coordination)
Chiesi Farmaceutici S.p.A
CHIESI Farmaceutici S.p.A.
SCHWEDEN
Region Uppsala
UPPSALA
IMPACTT: Immunoglobulin IgY pseudomonas A clinical trial for cystic fibrosis treatment
Uppsala University
VEREINIGTE STAATEN
California
FOSTER CITY
ALPINE2: Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects With Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas Aeruginosa (PA) Infection/Colonization
GILEAD SCIENCES, INC.
Gilead Sciences, Inc
VEREINIGTE STAATEN
Illinois
LAKE FOREST
VEREINIGTE STAATEN
Massachusetts
CAMBRIDGE
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis
Vertex Pharmaceuticals Inc.
VEREINIGTE STAATEN
Massachusetts
CAMBRIDGE
A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
Vertex Pharmaceuticals Inc.
VEREINIGTE STAATEN
New Jersey
SOUTH PLAINFIELD
A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis (coordination)
PTC Therapeutics Inc.
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
TRAFFIC: A phase 3, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of Lumacaftor in combination with Ivacaftor in patients aged 12 years and older with Cystic Fibrosis, homozygous for the F508del CFTR mutation
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A phase III, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of Lumacaftor in combination with Ivacaftor in subjects aged 12 Years and older with Cystic Fibrosis, homozygous for the F508del CFTR mutation
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who Are Homozygous for the F508del-CFTR Mutation
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Proteostasis PTI428: A Phase I/II Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects with Cystic Fibrosis
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US